ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/002/SRR5927362/SRR5927362.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/004/SRR5927364/SRR5927364.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/009/SRR5927359/SRR5927359.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/001/SRR5927361/SRR5927361.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/007/SRR5927357/SRR5927357.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/006/SRR5927366/SRR5927366.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/005/SRR5927365/SRR5927365.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/008/SRR5927358/SRR5927358.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/008/SRR5927368/SRR5927368.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/000/SRR5927360/SRR5927360.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/007/SRR5927367/SRR5927367.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR592/003/SRR5927363/SRR5927363.fastq.gzprimaryOK200GenomicsGENE REGULATION, RESEARCH, PETER MACCALLUM CANCER CENTREhttps://www.ebi.ac.uk/ena/browser/view/PRJNA397984Homo sapiensGene expression profiling was performed to characterise transcriptional programs associated with response to type I JAK2 inhibitor ruxolitinib, type II JAK2 inhibitor CHZ868 or shRNA-mediated JAK2 knockdown in MHH-CALL4 cells. Overall design: CRLF2-rearranged/JAK2I682F-expressing MHH-CALL4 cells were treated with vehicle (DMSO), CHZ868 (300 nM) or ruxolitinib (1000 nM) for 24 hours in duplicate and total RNA was freshly extracted for 3'-RNA-Seq. MHH-CALL4 cells were transduced with constitutive (pLMS-GFP) retroviral vectors harbouring shRNAs targeting JAK2 (shJAK2.209 or shJAK2.2826) or scrambled (shSCR) in duplicate and GFP+ cells were harvested at day 5 post-transduction for 3'-RNA-Seq.xref:PubMed:29907650ENAfalseHomo sapiensComparative gene expression profiling of MHH-CALL4 cells subject to pharmacological JAK2 inhibitor treatment (ruxolitinib or CHZ868) or shRNA-mediated JAK2 depletion in vitro2025-09-242018-01-02PRJNA397984GSE102534960629907650